NCI Eyes Some Budget Gains for FY2007

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

Congress finally resolved the current federal budget in mid-February, 4 months after fiscal year (FY) 2007 began, and raised the National Institutes of Health's funding to $28.9 billion, an increase of $619.5 million (2%) over its FY2006 appropriations.

BETHESDA, Maryland—Congress finally resolved the current federal budget in mid-February, 4 months after fiscal year (FY) 2007 began, and raised the National Institutes of Health's funding to $28.9 billion, an increase of $619.5 million (2%) over its FY2006 appropriations. Although Congress kept the National Cancer Institute's budget at $4.79 billion, the Institute gained approximately $42.8 million in additional dollars because it will not have to contribute to the NIH common fund this year. These dollar gains plus money from other sources should increase NCI's available dollars by $46 million, NCI director John E. Niederhuber, MD, said at a meeting of the National Cancer Advisory Board.

The money should enable NCI to provide $2.022 billion to fund 5,188 research project grants in FY2007, 16 more than in FY2006, he said. Noncompeting grants will fall to 3,878, a decrease of 14 from last fiscal year, and these grants will have no inflationary adjustments built into them. Competing grants will rise to 1,310, an increase of 30.

In his proposed budget for FY2008, President Bush asked Congress to provide NIH $28.9 billion and NCI $4.782 billion, decreases of $511 million and $11 million, respectively, from their newly approved FY2007 funding.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content